For response and loss of response to PEBD, the company used the utility for healthy children from Kamath et al. (2015). However, it applied a utility multiplier of 0.722 to represent the quality-of-life effect of having a stoma bag. This was taken from a study of adults with ulcerative colitis by Arseneau et al. (2006). For the PEBD loss-of-response health state, the company applied an additional disutility of 0.977 for short stature, reported in a study of children with chronic kidney disease by Al-Uzri et al. (2013). This resulted in utilities of 0.659 for PEBD response and 0.599 for PEBD loss of response. The company also presented scenario analyses using a stoma bag utility multiplier of 0.945 from a colorectal cancer study by Hornbrook et al. (2011) and its own utility elicitation study. (The exact value is academic in confidence and cannot be reported here.) The committee noted that most people in the colorectal cancer study were over 70 years old, so it was unlikely to be comparable to the population with PFIC. It also heard that the company's vignette study only used data from 2 carers of children with PFIC, so was not considered sufficiently robust to capture all stoma bag-related issues by the ERG. At the first committee meeting, the ERG chose to use a disutility multiplier of 0.833 in its base case. This was calculated by averaging the disutilities derived from the colorectal cancer and ulcerative colitis studies, and was preferred by the committee at the time. However, clinical expert feedback at consultation was that the disutility of a stoma bag for PEBD was expected to be comparable to that for ulcerative colitis. So, the ERG included the lower value of 0.722 in its updated base case. The clinical experts explained that the stoma-related effect on quality of life is significant, especially in older children. This is because the disutility may be larger for them compared with other age groups, and they often refuse an external biliary diversion. One clinical expert also highlighted that stoma-related quality of life was likely to be better for someone with colorectal cancer or ulcerative colitis than for someone with a stoma bag collecting bile. This is because the irritant nature of bile at the stoma site can cause problems including infection, which often needs treating with antibiotics and other interventions. At the second meeting, clinical experts also flagged the large volume of fluid loss with a PEBD stoma bag, sometimes up to 1 litre per day. In comparison, stoma bags for ulcerative colitis or colorectal cancer, which are located lower down the gastrointestinal tract, are associated with less fluid loss. The clinical experts agreed that literature utility multipliers from ulcerative colitis and colorectal cancer likely underestimated the quality-of-life effect of a stoma bag. One clinical expert stated that a utility multiplier derived from an infant with a stoma bag for necrotising fasciitis, which also has a high volume of fluid loss, would be more comparable to a PEBD. At the first committee meeting, the patient experts highlighted that people with PFIC and carers have a very negative attitude to having a stoma bag, and that sometimes the invasive surgery may not resolve the pruritus. Consultation comments supported this view, describing a stoma bag as "a great discomfort" and "shameful" for people with PFIC. The committee agreed that the disutility of living with a stoma bag was likely to be lower than the utility multipliers derived from both the ulcerative colitis and colorectal cancer studies. It noted that the utility multiplier from the company's elicitation study was considerably lower than the alternative values but recalled the small sample size informing the results. At the second meeting, the committee concluded that, in the absence of alternative sources, the utility multiplier derived from ulcerative colitis was most appropriate for decision making.